Evidence map›Paper›PMID 26662569›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.

Jingjing Li, Yanwei Ye, Min Wang, Lisha Lu, Chao Han, Yubing Zhou, Jingmin Zhang, Zujiang Yu, Xiefu Zhang, Chunlin Zhao and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jingjing LiDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanwei YeInstitute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, 1 Jian-She Road, Zhengzhou, 450052, China. yeyanwei1981@hotmail.com.
Min WangDepartment of Function, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lisha LuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chao HanDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yubing ZhouDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jingmin ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Zujiang YuDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiefu ZhangInstitute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, 1 Jian-She Road, Zhengzhou, 450052, China.
Chunlin ZhaoInstitute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, 1 Jian-She Road, Zhengzhou, 450052, China.
Jianguo WenInstitute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, 1 Jian-She Road, Zhengzhou, 450052, China.
Quancheng KanDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNFifth Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim was to investigate the function of fibroblast growth factor receptor 4 (FGFR4) in gastric cancer (GC) and explore the treatment value of agent targeted to FGFR4. Function assays in vitro and in vivo were performed to investigate the discrepancy of biological features among the GC cells with different expression of FGFR4. GC cells were treated with the single and combination of PD173074 (PD, an inhibitor of FGFR4) and 5-fluorouracil (5-Fu). The invasion ability were stronger, and the apoptosis rates were lower in MGC803 and BGC823 cells treated with FGFR4-LV5 (over-expression of FGFR4 protein) (P < 0.05). The proliferation ability of GC cells is reduced when treated by the single and combination of 5-Fu and PD while that of the FGFR4-LV5 group was less inhibited compared with control group (P < 0.05). The apoptosis rates are remarkably increased in GC cells treated with the single and combination of 5-Fu and PD (P < 0.05). However, the apoptosis rate obviously is reduced in GC cells treated with FGFR4-LV5 compared with control group (P < 0.05). The expression of PCNA and Bcl-XL is remarkably decreased, and the expression of Caspase-3 and cleaved Caspase-3 is obviously increased in GC cells treated with the single and combination of 5-Fu and PD. The tumor volumes of nude mice in FGFR4-LV5 group were much more increased (P < 0.05). The over-expression of FGFR4 enhanced the proliferation ability of GC in vitro and in vivo. The combination of 5-Fu and PD exerted synergetic effect in weakening the proliferation ability and promoting apoptosis in GC cells, while the over-expression of FGFR4 might inhibit the efficacy of two drugs.

Indexed as

Gene ExpressionAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalFluorouracilHumansMaleMicePyrimidinesReceptor, Fibroblast Growth Factor, Type 4Stomach NeoplasmsXenograft Model Antitumor AssaysFluorouracilPD 173074PyrimidinesReceptor, Fibroblast Growth Factor, Type 45-FluorouracilFGFR4Gastric cancerIn vivoPD173074

Identifiers

PMID26662569
OpenAlexW2296191529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.